Clinical Outcomes

Newly Introduced Bipartisan Bill Would Increase Public Awareness of Benefits of Pharmacogenetic Treatments

With a focus on pharmacogenomics testing, proposed legislation would boost public demand for precision medicine treatments and build better electronic infrastructure to support precision medicine.

Newly Introduced Bipartisan Bill Would Increase Public Awareness of Benefits of Pharmacogenetic Treatments Read More »

UMass Medical School Pilot Study Shows Modified Nucleotide Therapy Can Suppress Gene That Causes Lou Gehrig’s Disease

“While other teams have documented that this gene can be suppressed in cells in culture, this is the first time this type of antisense oligonucleotide treatment for C9ORF72 ALS has been demonstrated in a person with ALS.”

UMass Medical School Pilot Study Shows Modified Nucleotide Therapy Can Suppress Gene That Causes Lou Gehrig’s Disease Read More »

Rapid Genetic Sequencing Saves the Life of an Infant With a Rare Fatal Brain Disease

Research will continue toward the value and medical necessity of both WES and WGS where results directly influence medical management and clinical outcomes. As a result, reimbursement for the uses of these testing methods may be changing as more about their roles is learned.

Rapid Genetic Sequencing Saves the Life of an Infant With a Rare Fatal Brain Disease Read More »

UPenn Researchers Identify Genes Responsible for Kidney Function and Related Hypertension

Because of the increased number of risk adjustment programs, improved diagnosis and treatment of chronic kidney disease (CKD) could trigger substantial financial benefit. This research maps a path for physicians and health systems to better utilize existing medications for their patients with CKD.

UPenn Researchers Identify Genes Responsible for Kidney Function and Related Hypertension Read More »

Cardinal Health Participates in $160 Million Investment into Precision Medicine Radiopharmaceutical R&D in Indianapolis

The nuclear medicine hub in Indiana will generate research, discovery, and evidence of the safety and efficacy of radiopharmaceuticals at a time when the FDA recently has approved two molecular imaging drugs for prostate cancer.

Cardinal Health Participates in $160 Million Investment into Precision Medicine Radiopharmaceutical R&D in Indianapolis Read More »

Otolaryngology Group’s Adoption of Pharmacogenomics Shows How Hospitals Can Integrate Precision Medicine

A San Francisco-based otolaryngology practice recently implemented genetic-based treatment offerings. Lessons learned here could be used to guide other practice or hospital leaders that are developing a precision medicine strategy.

Otolaryngology Group’s Adoption of Pharmacogenomics Shows How Hospitals Can Integrate Precision Medicine Read More »

COVID-19 Highlights the Benefits of Using Digital Twins When Providing Precision Medicine

James Glazier, PhD, is a professor of intelligent systems at the Indiana Luddy School of Informatics, Computing, and Engineering. Dr. Glazier is uncovering new potential in the concept of “digital twins.” His findings were published in Science. What are digital twins and why are they becoming important for precision medicine?

COVID-19 Highlights the Benefits of Using Digital Twins When Providing Precision Medicine Read More »